Ingevity Corporation

NYSE:NGVT Stok Raporu

Piyasa değeri: US$2.3b

Ingevity Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Ingevity şirketinin gelirinin yıllık 3.1% oranında düşmesi, yıllık kazançlarının ise yıllık 78.7% oranında artması bekleniyor. EPS'nin yıllık 78.4% oranında büyümesi bekleniyor.

Anahtar bilgiler

78.7%

Kazanç büyüme oranı

78.40%

EPS büyüme oranı

Chemicals kazanç büyümesi17.2%
Gelir büyüme oranı-3.1%
Gelecekteki özkaynak getirisin/a
Analist kapsamı

Low

Son güncelleme12 May 2026

Gelecekteki son büyüme güncellemeleri

Recent updates

Seeking Alpha • May 19

Ingevity - Shrinking To Grow

Summary Ingevity is pursuing a shrink-to-grow strategy, divesting non-core assets to boost focus and margins. Recent asset sales fetched modest prices, following significant impairment charges, but have not materially impacted earnings. Ingevity´s leverage is gradually declining, with 2026 guidance targeting $4.70–$5.20 EPS and $370–$395 million adjusted EBITDA. I remain cautiously optimistic, seeing potential for re-rating if further simplification or a performance materials spin-off occurs. Read the full article on Seeking Alpha
Anlatı Güncellemesi • May 14

NGVT: Future P/E Will Reward Margin Strength Despite Recent Impairment Charge

Analysts have raised Ingevity's price target from $80.50 to $85.50, citing updated assumptions for discount rates, revenue growth, profit margins, and future P/E that they believe more accurately reflect the stock's risk and earnings profile. What's in the News Ingevity reaffirmed earnings guidance for full year 2026, with expected net sales in a range of $1.05b to $1.15b (company guidance).
Anlatı Güncellemesi • Apr 28

NGVT: Future P/E Will Reflect Margin Resilience And Impairment Charge Impact

Analysts have increased their price target for Ingevity to $80.50 from $79.25, citing updated assumptions on long term revenue growth, profit margin resilience, and future P/E levels reflected in recent research, including the Wells Fargo target increase. Analyst Commentary Recent research behind the new US$80.50 price target focuses on refreshed assumptions for long term revenue trends, margin resilience, and the P/E level that investors may be willing to ascribe to Ingevity over time.
Anlatı Güncellemesi • Apr 11

NGVT: Future P/E Will Depend On Margin Execution And Impairment Fallout

Analysts have raised their price target on Ingevity by $5 to $79.25, citing updated assumptions regarding discount rates, long-term revenue growth, profit margins, and future P/E expectations. Analyst Commentary Analysts raising the price target to $79.25 are updating their models to reflect changes in discount rates, long term revenue assumptions, profit margins, and future P/E expectations.
Anlatı Güncellemesi • Mar 28

NGVT: Higher P/E Will Rely On Future Margin Delivery

Analysts have lifted their price target on Ingevity by $5 to $79.25, citing updated assumptions on discount rates, long term revenue growth, profit margins, and future P/E, which support a slightly higher valuation outlook. Analyst Commentary Bullish Takeaways Bullish analysts see the higher price target as consistent with updated assumptions on discount rates and long term revenue growth, which they believe better reflect the company’s current risk profile and earnings potential.
Anlatı Güncellemesi • Mar 13

NGVT: Higher P/E Outlook Will Depend On Margin Execution

Analysts have raised their price target on Ingevity by $8.50 to $79.25, citing updated views on revenue growth, profit margins, and an expected higher future P/E multiple. Analyst Commentary Recent Street research has focused on how Ingevity might justify a higher valuation, with specific attention on revenue trends, profitability, and the potential for the shares to support a richer P/E multiple over time.
Anlatı Güncellemesi • Feb 24

NGVT: Updated P/E Assumptions And Buybacks Will Shape Balanced Outlook

Analysts have raised their price target on Ingevity by $5 to $70.75, citing updated assumptions around discount rates and future P/E as the main factors behind this revised view. Analyst Commentary Analysts framing the new US$70.75 price target are focusing less on short term headlines and more on what updated discount rate and P/E assumptions imply for Ingevity's risk profile and execution needs.
Anlatı Güncellemesi • Feb 09

NGVT: Share Repurchases And Battery Materials License Will Guide Balanced Outlook

Analysts have raised their price target on Ingevity from US$69.50 to US$70.75, citing updated assumptions around discount rates, revenue trends, profit margins and future P/E expectations. Analyst Commentary Analysts who support the higher price target describe it as a fine tuning of their models rather than a wholesale rethink.
Anlatı Güncellemesi • Jan 26

NGVT: Buybacks And Battery Materials License Will Shape Balanced Outlook

Analysts have maintained their fair value estimate for Ingevity at US$69.50, with only minor adjustments to inputs such as the discount rate and long-term P/E assumptions. These changes reflect updated modeling rather than a change in conviction.
Anlatı Güncellemesi • Jan 10

NGVT: Battery Additives And Buybacks Will Shape Balanced Long-Term Outlook

Analysts have adjusted their price target on Ingevity to US$69.50. This reflects updated views on the discount rate, revenue outlook, profit margins and future P/E assumptions.
Anlatı Güncellemesi • Dec 25

NGVT: Future Battery Materials Role Will Drive Long-Term Upside Despite Margin Reset

Analysts have modestly raised their price target on Ingevity by about $1.25 to approximately $69.50. They cite a lower perceived discount rate and an improving revenue trajectory, which more than offset concerns about a structurally lower profit margin and a higher future valuation multiple.
Anlatı Güncellemesi • Dec 10

NGVT: Future Battery Materials Role Will Drive Stronger Long Term Upside Potential

Analysts have nudged their price target on Ingevity higher from $65.25 to $68.25, citing a modestly richer future earnings multiple that more than offsets slightly softer revenue growth and margin assumptions. What's in the News Ingevity announced that Executive Vice President and Chief Financial Officer Mary Dean Hall will transition from her role effective May 1, 2026, and remain in an advisory capacity for one year, as part of a planned leadership change.
Analiz Makalesi • Sep 30

Is There Now An Opportunity In Ingevity Corporation (NYSE:NGVT)?

While Ingevity Corporation ( NYSE:NGVT ) might not have the largest market cap around , it received a lot of attention...
Analiz Makalesi • Sep 06

Does Ingevity (NYSE:NGVT) Have A Healthy Balance Sheet?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Anlatı Güncellemesi • Sep 05

Portfolio Repositioning And Engineered Additives Will Create A Sustainable Future

Consensus analyst price targets for Ingevity have risen to $65.25, reflecting increased confidence in continued earnings and free cash flow growth following a strong Q2 beat and improved operational outlook. Analyst Commentary Q2 earnings beat, demonstrating stronger-than-expected financial performance.
Anlatı Güncellemesi • Aug 06

Portfolio Repositioning And Engineered Additives Will Create A Sustainable Future

The upward revision in Ingevity's revenue growth forecasts from 2.6% to 3.7% per annum has outweighed the impact of a higher discount rate, resulting in an increased consensus analyst price target from $54.25 to $57.00. What's in the News Ingevity Corporation maintained its earnings guidance for 2025, expecting sales between $1.25 billion and $1.40 billion.
Analiz Makalesi • Jun 27

Ingevity Corporation (NYSE:NGVT) Shares Could Be 39% Below Their Intrinsic Value Estimate

Key Insights The projected fair value for Ingevity is US$71.30 based on 2 Stage Free Cash Flow to Equity Ingevity's...
Analiz Makalesi • May 28

Subdued Growth No Barrier To Ingevity Corporation (NYSE:NGVT) With Shares Advancing 33%

Those holding Ingevity Corporation ( NYSE:NGVT ) shares would be relieved that the share price has rebounded 33% in the...
User avatar
Yeni Anlatı • May 27

Premium Markets Will Secure Long Term Value

Expansion into premium specialty chemicals and advanced materials is increasing margins and positioning for growth as sustainability trends and vehicle electrification accelerate.
Analiz Makalesi • Apr 05

Why We're Not Concerned Yet About Ingevity Corporation's (NYSE:NGVT) 32% Share Price Plunge

Ingevity Corporation ( NYSE:NGVT ) shares have had a horrible month, losing 32% after a relatively good period...
Analiz Makalesi • Feb 20

Ingevity (NYSE:NGVT) Has A Somewhat Strained Balance Sheet

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Analiz Makalesi • Jan 16

Ingevity Corporation (NYSE:NGVT) Shares Could Be 49% Below Their Intrinsic Value Estimate

Key Insights Ingevity's estimated fair value is US$82.84 based on 2 Stage Free Cash Flow to Equity Ingevity is...
Analiz Makalesi • Nov 07

What Ingevity Corporation's (NYSE:NGVT) 32% Share Price Gain Is Not Telling You

Ingevity Corporation ( NYSE:NGVT ) shareholders have had their patience rewarded with a 32% share price jump in the...
Analiz Makalesi • Oct 13

Is Ingevity (NYSE:NGVT) A Risky Investment?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analiz Makalesi • Sep 08

Ingevity Corporation's (NYSE:NGVT) Prospects Need A Boost To Lift Shares

When you see that almost half of the companies in the Chemicals industry in the United States have price-to-sales...
Seeking Alpha • Aug 27

Ingevity: The Risk-Reward Ratio Is Still Unfavorable

Summary Ingevity, once considered a growth story, turned out to be a classic example of market cycles. While Road Technology and Performance Materials performed reasonably well in the first half of 2024, the Industrial Specialties segment dragged down revenue and net income. Given the company's significant debt burden, risk-averse investors should seek safer options within the chemical industry. Read the full article on Seeking Alpha
Analiz Makalesi • Aug 03

Ingevity Corporation Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

There's been a notable change in appetite for Ingevity Corporation ( NYSE:NGVT ) shares in the week since its quarterly...
Analiz Makalesi • Jul 13

Ingevity (NYSE:NGVT) Use Of Debt Could Be Considered Risky

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analiz Makalesi • Jun 14

Should You Investigate Ingevity Corporation (NYSE:NGVT) At US$45.90?

Ingevity Corporation ( NYSE:NGVT ), might not be a large cap stock, but it received a lot of attention from a...
Analiz Makalesi • Apr 18

Are Investors Undervaluing Ingevity Corporation (NYSE:NGVT) By 44%?

Key Insights Ingevity's estimated fair value is US$78.59 based on 2 Stage Free Cash Flow to Equity Current share price...
Analiz Makalesi • Mar 22

Is Ingevity (NYSE:NGVT) A Risky Investment?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analiz Makalesi • Jan 23

What Is Ingevity Corporation's (NYSE:NGVT) Share Price Doing?

Ingevity Corporation ( NYSE:NGVT ), might not be a large cap stock, but it saw a double-digit share price rise of over...
Analiz Makalesi • Jan 04

Ingevity Corporation (NYSE:NGVT) Doing What It Can To Lift Shares

With a price-to-earnings (or "P/E") ratio of 12.6x Ingevity Corporation ( NYSE:NGVT ) may be sending bullish signals at...
Analiz Makalesi • Nov 10

These Analysts Just Made An Incredible Downgrade To Their Ingevity Corporation (NYSE:NGVT) EPS Forecasts

The latest analyst coverage could presage a bad day for Ingevity Corporation ( NYSE:NGVT ), with the analysts making...

Kazanç ve Gelir Büyüme Tahminleri

NYSE:NGVT - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/20281,0821882623213
12/31/20271,0761862443064
12/31/20261,0991252603244
3/31/20261,178-156246304N/A
12/31/20251,168-150274331N/A
9/30/20251,382-361240299N/A
6/30/20251,383-354150215N/A
3/31/20251,108-3695166N/A
12/31/20241,200-12151129N/A
9/30/20241,309-25828110N/A
6/30/20241,421-28072169N/A
3/31/20241,640-11287188N/A
12/31/20231,21610695205N/A
9/30/20231,704127128257N/A
6/30/20231,740177120252N/A
3/31/20231,678202154294N/A
12/31/20221,668212171313N/A
9/30/20221,621225160291N/A
6/30/20221,516146171291N/A
3/31/20221,454130152266N/A
12/31/20211,392118190293N/A
9/30/20211,381135273370N/A
6/30/20211,336209272360N/A
3/31/20211,248185264343N/A
12/31/20201,216181270352N/A
9/30/20201,194180199285N/A
6/30/20201,222170222313N/A
3/31/20201,304206238344N/A
12/31/20191,293184N/A276N/A
9/30/20191,268182N/A276N/A
6/30/20191,219171N/A252N/A
3/31/20191,175161N/A234N/A
12/31/20181,134169N/A252N/A
9/30/20181,085169N/A207N/A
6/30/20181,037153N/A193N/A
3/31/2018989138N/A178N/A
12/31/2017972127N/A174N/A
9/30/201795494N/A187N/A
6/30/201794253N/A144N/A
3/31/201792745N/A131N/A
12/31/201690835N/A128N/A
9/30/201689834N/A111N/A
6/30/201690264N/A100N/A
3/31/201691966N/A92N/A
12/31/201595880N/A72N/A
9/30/201599999N/A76N/A
6/30/20151,025115N/A111N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: NGVT önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 3.5% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: NGVT önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: NGVT önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: NGVT şirketinin gelirinin önümüzdeki 3 yıl içinde düşmesi bekleniyor (yılda -3.1% ).

Yüksek Büyüme Geliri: NGVT şirketinin gelirinin önümüzdeki 3 yıl içinde düşmesi öngörülüyor (yılda -3.1% ).

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: NGVT 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Büyüyen şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/05/24 18:39
Gün Sonu Hisse Fiyatı2026/05/22 00:00
Kazançlar2026/03/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Ingevity Corporation 8 Bu analistlerden 4, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Paretosh MisraBerenberg
John McNultyBMO Capital Markets Equity Research
Jonathan TanwantengCJS Securities, Inc.